Trevi Therapeutics, Inc.
(NASDAQ : TRVI)

( )
TRVI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.82%33.750.9%$1145.03m
JNJJohnson & Johnson 0.29%143.270.7%$1079.06m
BMYBristol-Myers Squibb Co. -1.19%59.571.0%$967.54m
MRKMerck & Co., Inc. -1.07%77.880.7%$816.26m
ABBVAbbVie, Inc. -0.03%99.321.9%$785.33m
LLYEli Lilly & Co. 1.42%169.121.1%$695.99m
AZNAstraZeneca Plc 1.35%54.191.2%$290.07m
VXRTVaxart, Inc. -8.12%8.150.0%$286.48m
RPRXRoyalty Pharma Plc 2.06%48.020.1%$226.50m
NVSNovartis AG 0.36%88.120.2%$151.51m
RGENRepligen Corp. 0.92%125.287.2%$117.23m
GSKGlaxoSmithKline Plc 0.84%40.720.2%$112.42m
NVONovo Nordisk A/S 1.25%65.870.1%$94.18m
RETAReata Pharmaceuticals, Inc. 1.52%158.003.4%$82.12m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 8.02%77.860.0%$73.21m

Company Profile

Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.